文献速递心力衰竭与心肌病高血压

心脏成纤维细胞ATF3通过抑制MAP2K3-p38信号保护心力衰竭

Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
PubMed 文献 · Circulation · 2017-03-01

该研究采用无偏发现方法与功能获得/缺失策略,发现高血压心脏中ATF3表达升高,心脏成纤维细胞是主要表达细胞;ATF3敲除加重高血压心室重构,而成纤维细胞特异性过表达ATF3改善重构与心衰;机制上ATF3结合Map2K3启动子并招募HDAC1抑制其表达,进而抑制p38-TGF-β信号。

要点

  • 高血压心脏中ATF3表达升高,心脏成纤维细胞是主要表达细胞类型。
  • 成纤维细胞特异性过表达ATF3改善心室重构与心衰,ATF3敲除则加重。
  • ATF3通过招募HDAC1抑制Map2K3表达,进而抑制p38-TGF-β促纤维化信号。

核心结论

  • 研究首次提供证据表明,心脏成纤维细胞中ATF3响应高血压刺激而上调,通过抑制Map2K3表达及后续p38-TGF-β信号保护心脏。
  • 作者认为正向调控心脏成纤维细胞ATF3可能代表一种对抗高血压心脏重构的新治疗途径。

研究设计与样本

  • 研究采用发现驱动的无偏方法识别高血压心脏中升高的ATF3表达。
  • 研究使用功能缺失与功能获得方法探究ATF3在心衰中的作用,并结合转录组、染色质免疫沉淀测序分析及体内外实验。

主要发现

  • ATF3表达在小鼠高血压心脏和人类肥厚心脏中升高,心脏成纤维细胞是响应高血压刺激表达高水平ATF3的主要细胞类型。
  • ATF3敲除显著加重高血压心室重构,该状态可被慢病毒介导/miRNA辅助的心脏成纤维细胞选择性ATF3过表达所挽救。
  • 条件性心脏成纤维细胞特异性ATF3转基因过表达显著改善心室重构和心力衰竭。
  • ATF3与Map2K3启动子结合并招募HDAC1,导致Map2K3基因相关组蛋白去乙酰化,从而抑制Map2K3表达;遗传性Map2K3敲低可挽救ATF3KO细胞的促纤维化/肥厚表型。
  • p38是Map2K3下游分子,介导ATF3KO动物的促纤维化/肥厚效应;抑制p38信号减少TGF-β信号相关的促纤维化和肥厚基因表达,并阻断ATF3KO细胞中加重的心脏重构。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive ventricular remodeling is a common cause of heart failure. However, the molecular mechanisms regulating ventricular remodeling remain poorly understood. METHODS: We used a discovery-driven/nonbiased approach to identify increased activating transcription factor 3 (ATF3) expression in hypertensive heart. We used loss/gain of function approaches to understand the role of ATF3 in heart failure. We also examined the mechanisms through transcriptome, chromatin immunoprecipitation sequencing analysis, and in vivo and in vitro experiments. RESULTS: ATF3 expression increased in murine hypertensive heart and human hypertrophic heart. Cardiac fibroblast cells are the primary cell type expressing high ATF3 levels in response to hypertensive stimuli. ATF3 knockout (ATF3KO) markedly exaggerated hypertensive ventricular remodeling, a state rescued by lentivirus-mediated/miRNA-aided cardiac fibroblast-selective ATF3 overexpression. Conversely, conditional cardiac fibroblast cell-specific ATF3 transgenic overexpression significantly ameliorated ventricular remodeling and heart failure. We identified Map2K3 as a novel ATF3 target. ATF3 binds with the Map2K3 promoter, recruiting HDAC1, resulting in Map2K3 gene-associated histone deacetylation, thereby inhibiting Map2K3 expression. Genetic Map2K3 knockdown rescued the profibrotic/hypertrophic phenotype in ATF3KO cells. Last, we demonstrated that p38 is the downstream molecule of Map2K3 mediating the profibrotic/hypertrophic effects in ATF3KO animals. Inhibition of p38 signaling reduced transforming growth factor-β signaling-related profibrotic and hypertrophic gene expression, and blocked exaggerated cardiac remodeling in ATF3KO cells. CONCLUSIONS: Our study provides the first evidence that ATF3 upregulation in cardiac fibroblasts in response to hypertensive stimuli protects the heart by suppressing Map2K3 expression and subsequent p38-transforming growth factor-β signaling. These results suggest that positive modulation of cardiac fibroblast ATF3 may represent a novel therapeutic approach against hypertensive cardiac remodeling.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Li Y, Li Z, Zhang C, et al. Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling. Circulation. 2017. PMID: 28249877. doi:10.1161/CIRCULATIONAHA.116.024599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。